Glizorem

Glizorem is a prescription oral medication that contains the active ingredient gliclazide, a sulfonylurea‑type antidiabetic. It is supplied as tablets (strengths may vary) and is marketed in the European Union. The drug stimulates insulin release from pancreatic beta cells, helping to lower blood glucose in adults with type 2 diabetes mellitus, and is usually considered when diet, exercise, and other oral agents do not achieve glycemic targets.

Glizorem is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet, exercise, and lifestyle modifications.

- Improves glycemic control in adults with type 2 diabetes when monotherapy or combination therapy is appropriate. - Can be used as an add‑on to metformin or other oral antidiabetic agents. - May be considered in patients who have inadequate response to other sulfonylureas. - Suitable for use in patients with stable renal function and without severe hepatic impairment. - May be prescribed when a once‑daily oral hypoglycemic is preferred.

Like other sulfonylureas, Glizorem may cause a range of side effects; they are generally classified by frequency and severity.

Common: - Mild to moderate hypoglycemia, especially if meals are missed or delayed. - Weight gain due to increased insulin activity. - Nausea, abdominal discomfort, or diarrhoea. - Dizziness or headache.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as skin rash, pruritus, or angioedema. - Rare blood disorders like agranulocytosis or thrombocytopenia.

Before starting Glizorem, healthcare providers should evaluate several clinical factors to minimize risks and ensure appropriate use.

- Assess renal and hepatic function; dose adjustment may be needed in impairment. - Review history of hypoglycemia or adrenal insufficiency. - Use caution in elderly patients due to increased sensitivity to hypoglycemia. - Monitor blood glucose regularly, especially during therapy initiation or dose changes. - Avoid use in patients with known sulfonylurea allergy. - Consider pregnancy and lactation status; benefits must outweigh potential risks. - Evaluate concomitant use of drugs that affect insulin secretion.

Glizorem can interact with other medicines, altering blood glucose levels or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise gliclazide concentrations. - MAO‑B inhibitors, which may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may reduce glucose‑lowering efficacy. - Anticoagulants (e.g., warfarin), as gliclazide may affect INR monitoring.